Immunic announces start of patient cohorts in its phase 1 clinical trial of imu-856 in celiac disease

– first time patients will be treated with the company's orally available small molecule modulator targeting restoration of intestinal barrier function and regeneration of bowel epithelium  – new york , may 5, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the start of the patient cohorts in its ongoing phase 1 clinical trial of imu-856, the company's third clinical asset, in patients with celiac disease. imu-856 is an orally available and systemically acting small molecule modulator that targets an undisclosed epigenetic regulator.
IMUX Ratings Summary
IMUX Quant Ranking